1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain

Trial Profile

1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 12 Feb 2016

At a glance

  • Drugs Ziprasidone (Primary) ; Aripiprazole; Quetiapine; Risperidone
  • Indications Autistic disorder; Bipolar disorders; Bipolar I disorders; Mania; Mood disorders; Schizophrenia
  • Focus Adverse reactions
  • Most Recent Events

    • 04 Feb 2016 Status changed from not yet recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 09 May 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top